Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 plus panitumumab in metastatic colorectal cancer with mutant or wild-type RAS
NL-OMON41524Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of binimetinib and panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Pfizer. Primary endpoints: Incidence of dose-limiting toxicities in Cycle 1 and Overall response rate. Started Feb 2014; status: recruiting.
02
Drugs
binimetinibpanitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON41524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41524.